[Corrigendum] Targeting cysteine‑rich angiogenic inducer‑61 by antibody immunotherapy suppresses growth and migration of non‑small cell lung cancer

Li,Xinpeng; Yuan,Naxin; Lin,Lingdan; Yin,Lixia; Qu,Yiqing

doi:10.3892/etm.2022.11365

July-2022 Volume 24 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2022 Volume 24 Issue 1

Full Size Image

Correction Open Access

[Corrigendum] Targeting cysteine‑rich angiogenic inducer‑61 by antibody immunotherapy suppresses growth and migration of non‑small cell lung cancer

Authors:
- Xinpeng Li
- Naxin Yuan
- Lingdan Lin
- Lixia Yin
- Yiqing Qu
View Affiliations / Copyright

Affiliations: Department of Respiration, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Respiration, Dezhou People's Hospital, Dezhou, Shandong 253014, P.R. China, Department of Cardiology, Dezhou People's Hospital, Dezhou, Shandong 253014, P.R. China

Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article Number: 438
|
Published online on: May 11, 2022

https://doi.org/10.3892/etm.2022.11365
Expand metrics +

Article

Exp Ther Med 16:[Related article:] 730–738, 2018; DOI: 10.3892/etm.2018.6274

Following the publication of this paper, it was drawn to the attention of the Editorial Office by a concerned reader that the western blots featured in Fig. 4C and E on p. 736 appeared to have been misplaced, or were possibly mislabelled. After having asked the authors for an explanation to account for the problematic appearance of this figure, they realized that errors were made during the compilation of this figure, and supplied a new version of this figure to the office containing new data which rectifies the problems that were identified. The new version of Fig. 4 is shown below. All the authors agree with the publication of this corrigendum, and thank the Editor of Experimental and Therapeutic Medicine for allowing them the opportunity to publish this. Furthermore, they apologize to the readership for any inconvenience caused.

Figure 4

Effect of anti-CYR-61 on apoptosis in NSCLC cells. (A) Fluorescence-activated cell sorting was used to evaluate the apoptosis of H358 cells after anti-CYR-61 treatment. Apoptosis-related (B) mRNA and (C) protein expression levels in an exogenous cell apoptosis signaling pathway were analyzed in anti-CYR-61-treated cells. Apoptosis-related (D) mRNA and (E) protein expression levels in the mitochondrial apoptosis pathway were analyzed in anti-CYR-61-treated cells. Data are presented as the mean ± standard deviation of triplicate samples. **P<0.01 vs. the control. CYR-61, cysteine-rich angiogenic inducer-61; NSCLC, non-small-cell lung cancer; FasL, Fas ligand; FADD, Fas-associated protein with Death Domain; Bak, B cell lymphoma-2 antagonist/killer; Bax, B cell lymphoma-2-associated X protein; Apaf-1, apoptotic protease activating factor 1.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

[Corrigendum] Targeting cysteine‑rich angiogenic inducer‑61 by antibody immunotherapy suppresses growth and migration of non‑small cell lung cancer

This article is mentioned in:

Article

Figure 4

Related Articles